Elobixibat
Also known as: A3309, AZD7806, Goofice
Source Elobixibat at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Elobixibat is a minimally absorbed, locally acting ileal bile acid transporter inhibitor approved in Japan for the treatment of chronic idiopathic constipation. By blocking bile acid reabsorption in the terminal ileum, it accelerates colonic transit and increases fluid secretion into the colon.
Mechanism of Action
Inhibits the apical sodium-dependent bile acid transporter (ASBT/SLC10A2) in the terminal ileum, reducing reabsorption of bile acids and increasing their delivery to the colon, which stimulates colonic motility and secretion via TGR5 and FXR pathways.
Routes of Administration
Goals & Uses
- Relief of chronic idiopathic constipationGastroenterologyHigh
- Treatment of constipation-predominant IBS (IBS-C)GastroenterologyModerate
- Improvement of stool consistencyGastroenterologyHigh
- Reduction of LDL cholesterolCardiovascular/MetabolicLow
Contraindications
- Bowel obstructionGastrointestinalHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Hypersensitivity to elobixibatAllergyHigh
- Severe inflammatory bowel disease (acute phase)GastrointestinalHigh
Adverse Effects
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Elevated liver enzymes (transaminases)HepaticRare
- FlatulenceGastrointestinalCommonExcess gas in the digestive tract
- Abdominal pain/crampingGastrointestinalCommon
- DiarrheaGastrointestinalCommonLoose or frequent stools
Drug Interactions
- Lipid-lowering agents (statins)Low
- Bile acid sequestrants (e.g., cholestyramine)Moderate
- Oral medications with narrow therapeutic indexModerate
Population Constraints
- Nursing mothersReproductiveRelative
- Pediatric patientsAgeRelative
- Elderly patients (≥75 years)AgeRelative
- Patients with severe hepatic impairmentHepaticRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionUnapprovedNot approved by EMA; development in Europe did not progress to approval.
- United StatesUnapprovedPhase II/III trials were conducted; not submitted for or received FDA approval as of knowledge cutoff.
- United KingdomUnapprovedNot approved by MHRA.
Approved in Japan (2018) by PMDA under the brand name Goofice for chronic idiopathic constipation. Not approved by the FDA or EMA as of the knowledge cutoff; clinical trials in Western markets were conducted but regulatory approval was not pursued in those jurisdictions.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Elobixibat?
Elobixibat is a minimally absorbed, locally acting ileal bile acid transporter inhibitor approved in Japan for the treatment of chronic idiopathic constipation. By blocking bile acid reabsorption in the terminal ileum, it accelerates colonic transit and increases fluid secretion into the colon.
What is Elobixibat used for?
Elobixibat is educationally associated with: Relief of chronic idiopathic constipation, Treatment of constipation-predominant IBS (IBS-C), Improvement of stool consistency, Reduction of LDL cholesterol. Educational only — not medical advice.
How is Elobixibat administered?
Recorded routes of administration: Oral.
What are the potential side effects of Elobixibat?
Reported adverse effects include: Nausea, Elevated liver enzymes (transaminases), Flatulence, Abdominal pain/cramping, Diarrhea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Elobixibat?
Recorded contraindications: Bowel obstruction, Pregnancy, Hypersensitivity to elobixibat, Severe inflammatory bowel disease (acute phase). Consult a qualified clinician before use.